About: Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Jonathan L Kaufman et al published 4 January 2019 in Blood Cancer Journal

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 2019 (uk) article scientifique publié en 2019 (fr) im Januar 2019 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Jonathan L Kaufman et al published 4 January 2019 in Blood Cancer Journal (en)
publication date	wds:Q60920589-5C59FF3E-B4DC-4802-8A56-0FDCFABC6C12
publication date	2019-01-04 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q60920589-4D27D4D3-5B9F-40E4-A38F-CFE3BDCB06CE
language of work or name	English
exact match	wds:Q60920589-7BB7EFFF-03DE-40DB-89FB-66F25EAB3F0B
exact match	https://scigraph.springernature.com/pub.10.1038/s41408-018-0154-8
cites work	wds:Q60920589-1A372B73-3184-4212-9240-82ADC2B6B5C0 wds:Q60920589-1EEBA63E-4B1E-42FE-A778-242D06D93326 wds:Q60920589-2B52503D-AA24-45C2-BDCD-3CFA12912268 wds:Q60920589-339A64F7-3376-4EDC-A01A-A809C627B28B wds:Q60920589-3A4037CE-6BDD-4979-97E0-3A9F179CA8D1 wds:Q60920589-3DF6DD9D-0C02-4E4C-81B9-51F15F57C926 wds:Q60920589-43B82CB1-8E5D-4B91-A0CC-1987835B0BB9 wds:Q60920589-49F9376A-8BD3-457D-A3D2-3E18E9130A93 wds:Q60920589-5408F2EE-AC8D-4243-997E-5A99778905C2 wds:Q60920589-6E552542-0737-4AC0-B24A-D5814C9BC818 wds:Q60920589-7149B644-1CFF-4A37-A699-E64F903D70F0 wds:Q60920589-71E77DDA-EF89-45E8-B80D-DCB953707940 wds:Q60920589-7FB7CDDC-B285-4E0B-8A63-C17C7ADB0AA9 wds:Q60920589-8B054FC5-270D-4979-BADB-E03DCF0050FB wds:Q60920589-A3963784-79E1-4CE7-A96A-ED0261E5A6EB wds:Q60920589-A5853A43-9EB8-4B7B-AF10-DE81BA74B43C wds:Q60920589-A5C58775-A048-494D-ADEA-A90D08B2484E wds:Q60920589-ACC7910D-2404-4DAC-8162-329C97DCCDE7 wds:Q60920589-B4F4BC26-866A-4738-B62F-067F91FCBF25 wds:Q60920589-B663C11B-F23E-4E4C-950E-3E6C2D5D9DF3 wds:Q60920589-BD924C73-A47F-44CE-9A8F-4C6D46A528AB wds:Q60920589-E2CE64FF-EA29-4036-AD3C-285ADA9DD899 wds:Q60920589-F9039675-2CA2-45ED-A7AF-15314EFC3B2B
cites work	Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma International uniform response criteria for multiple myeloma. Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management Myeloma today: Disease definitions and treatment advances Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
author name string	wds:Q60920589-23E783A1-CC9B-411E-80A4-F876ACD73470 wds:Q60920589-34B0152A-E10F-4609-9D74-42A8F43792C6 wds:Q60920589-44D6D7B1-B219-498F-AF97-21608CC4EE6D wds:Q60920589-4B64DC0D-A1AB-467E-BF4A-34A02CD4B925 wds:Q60920589-6AEC0D2E-CD68-46A0-87BE-7B33C707C5A6 wds:Q60920589-A7D62610-B32B-44BB-A752-44547181915C wds:Q60920589-AFF4E1F2-EE5B-4DC4-91B9-B0A961049929 wds:Q60920589-C4D9EB3C-79F9-4F76-A3B6-CE8E7DB8AA6B wds:Q60920589-D6E47F27-3E94-4CA0-8AC0-E30F7A99EAD1 wds:Q60920589-DCF8391F-E60E-4745-AA29-DAB48DCA2ED9 wds:Q60920589-ED7EB6EC-B03E-4D01-9811-E15A1BD3DBD4 wds:Q60920589-F3EDA1AA-EC23-4A26-A6B6-E6A31BBCB95F
author name string	Thomas Martin Ajay K Nooka Charise Gleason R Donald Harvey Jonathan L Kaufman Andrzej J Jakubowiak Colleen Lewis Leonard T Heffner Cathy Sharp Roberto Mina Jeffrey J Wolf Todd L Zimmerman
rdfs:label	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (en) Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (nl)
skos:prefLabel	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (en) Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (nl)
name	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (en) Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (nl)
author	wds:Q60920589-FD3799CF-81A3-440E-A009-D5E4F3FF2141
author	Sagar Lonial
title	wds:Q60920589-608BD5AA-0DDD-4711-8E57-94A536B9FEB6
title	Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (en)
page(s)	wds:Q60920589-984BCD73-8722-47E9-8E3D-C931C9FC3581
page(s)	3
instance of	wds:Q60920589-18C440B9-64F5-433E-9863-131575FFA4FC
instance of	scholarly article
main subject	wds:Q60920589-4A8CB682-1D10-413C-B639-AF1E5F1DC342 wds:Q60920589-B63F7AC3-D745-4008-BEC3-DA4DC5D1F155
main subject	hematology multiple myeloma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software